Fig. 1: Expression of CALCRL and its ligand adrenomedullin and impact on patient outcome in AML.

a Genes overexpressed and associated with poor prognosis, relapse, or LSC vs HSC according to TCGA, Hackl et al.⁷ and Eppert et al.² studies, respectively. b Impact of CALCRL gene expression on overall survival in the TCGA cohort (Log-rank (Mantel-Cox) test). Data were dichotomized according to median value for visualization purpose. c CALCRL expression at diagnosis and relapse after intensive chemotherapy according to Hackl et al.⁷ (unpaired t-test). d CALCRL gene expression in normal compartments CD34⁺CD38⁻, CD34⁺CD38^low, progenitors, and Lin⁺ compared with leukemic LSC⁻ and LSC⁺ compartments according to Eppert et al.² (unpaired t-test) e, f Overall survival (OS) and event-free survival (EFS) according to CALCRL and ADM H-scores. OS and EFS were regressed against CALCRL and/or ADM H-scores using univariate or multivariate Cox model. Data were dichotomized for visualization purpose. g Representative IHC micrographs of CALCRL and ADM expression in pretherapeutic BM from AML patients. A picture of each primary sample was taken to make the quantifications. Scale bars correspond to 10 µm. h OS and EFS according to CALCRL and ADM H-scores. OS and EFS were regressed against CALCRL and/or ADM H-scores using univariate or multivariate Cox model. Data were dichotomized for visualization purpose.